Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

July 14, 2020July 14, 2020

University of Colorado Launches PreView Medical for PC Diagnosis, Treatment

News

The University of Colorado Anschutz Medical Campus, led by CU Innovations, has partnered with medical technology entrepreneurs Jonathan Gasson and Sharon Lake to form a new company called PreView Medical, ... Read more

July 9, 2020July 9, 2020

Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

News

YourVaccx, a new type of cancer vaccine developed by ImmunSYS, is safe and shows promising effectiveness in patients with metastatic prostate cancer and other difficult-to-treat advanced solid tumors, a proof-of-concept ... Read more

June 25, 2020June 25, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting the approval of relugolix for the ... Read more

June 16, 2020June 16, 2020

Cancer DNA Levels in Blood Can Predict Treatment Responses

News

Analyses of circulating tumor DNA (ctDNA) — DNA from cancer cells circulating in the bloodstream — in blood samples can be used to predict which men with advanced prostate cancer ... Read more

June 9, 2020June 9, 2020

U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

News

Genetic screenings of the general population for prostate cancer are feasible, safe, and may be effective at identifying the disease in apparently healthy men who might otherwise remain undiagnosed, according ... Read more

May 8, 2020May 8, 2020

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

News

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase 2 ... Read more

April 17, 2020April 17, 2020

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

News

A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from ... Read more

February 24, 2020February 24, 2020

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

News

The combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) is safe and shows clinically meaningful activity, leading to lasting responses in men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 1b trial ... Read more

October 24, 2019October 25, 2019

Prostate Cancer Patients May Safely Skip Radiation Therapy After Surgery, Phase 3 Trial Shows

News

Men with prostate cancer who undergo surgery have similar long-term outcomes whether they receive radiation therapy shortly after the surgery or only when signs of disease recurrence appear, suggesting that ... Read more

October 17, 2019

Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows

News

Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without compromising ... Read more